Silence Therapeutics PLC SLNCF:OTCPK

*Data is delayed | Exchange | USD
Last | 03/28/24 EDT
7.50quote price arrow down-1.50 (-16.67%)
Volume
1,810
52 week range
0.60 - 10.90
Loading...
  • Open7.50
  • Day High7.59
  • Day Low7.50
  • Prev Close9.00
  • 52 Week High10.90
  • 52 Week High Date03/20/24
  • 52 Week Low0.60
  • 52 Week Low Date08/29/23

Key Stats

  • Market Cap348.767M
  • Shares Out46.50M
  • 10 Day Average Volume1,525.83
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change400

KEY STATS

  • Open7.50
  • Day High7.59
  • Day Low7.50
  • Prev Close9.00
  • 52 Week High10.90
  • 52 Week High Date03/20/24
  • 52 Week Low0.60
  • 52 Week Low Date08/29/23
  • Market Cap348.767M
  • Shares Out46.50M
  • 10 Day Average Volume1,525.83
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change400

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-59.259M
  • ROE (TTM)-157.47%
  • Revenue (TTM)35.438M
  • Gross Margin (TTM)54.24%
  • Net Margin (TTM)-151.98%
  • Debt To Equity (MRQ)1.58%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Silence Therapeutics PLC

 

Profile

MORE
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include...
Iain Ross
Non-Executive Chairman of the Board
Craig Tooman
President, Chief Executive Officer, Executive Director
Address
72 Hammersmith Road
London
W14 8TH
United Kingdom